Study of bemotuzumab plus chemo and anlotinib for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer that has spread beyond one lung.
- You have not had any previous treatment for this stage of cancer.
- You are between 18 and 75 years old.
- You are able to do your daily activities with little help (ECOG score 0-2).
- Your major organs (kidneys, liver, heart, blood) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a combination of two drugs—lomustine (a chemotherapy) and anlotinib (a targeted therapy)—in patients whose small cell lung cancer has stopped responding to at least two previous treatment regimens. The goal is to see if this combination can slow or stop the cancer's growth.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests different treatments for people with extensive-stage small cell lung cancer who have not had prior therapy. It aims to find which treatment works best based on the unique features of your cancer.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.